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Introduction: Although lobectomy is considered the standard sur-
gical treatment for stage IA non–small-cell lung cancer (NSCLC), 
wedge resection or segmentectomy are frequently performed on 
patients who are not lobectomy candidates. The objective of this 
study was to compare survival among patients with stage IA NSCLC, 
who are undergoing these procedures.
Methods: Using the Surveillance, Epidemiology and End Results 
registry, we identified 3525 patients. We used logistic regression to 
determine propensity scores for patients undergoing segmentectomy, 
based on the patient’s preoperative characteristics. Overall and lung 
cancer-specific survival of patients treated with wedge resection 
versus segmentectomy was compared after adjusting, stratifying, or 
matching patients based on propensity score.
Results: Overall, 704 patients (20%) underwent segmentectomy. 
Analyses, adjusting for propensity scores, showed that segmentec-
tomy was associated with significant improvement in overall (hazard 
ratio: 0.80, 95% confidence interval: 0.69–0.93) and lung cancer-
specific survival (hazard ratio: 0.72, 95% confidence interval: 0.59–
0.88) compared with wedge resection. Similar results were obtained 
when stratifying and matching by propensity score and when limiting 
analysis to patients with tumors sized less than or equal to 2 cm, or 
aged 70 years or younger.
Conclusions: These results suggest that segmentectomy should be 
the preferred technique for limited resection of patients with stage 
IA NSCLC. The study findings should be confirmed in prospective 
studies.
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Although the majority of patients with non–small-cell lung cancer (NSCLC) are diagnosed at an advanced stage and 
have a poor prognosis, the long-term outcomes of the 10% to 
15% of patients diagnosed with stage IA disease are relatively 
good.1 The literature shows that resected patients with stage 
IA disease have 5-year overall survival rates more than 70% 
and outcomes are even better for patients with tumors sized 
less than or equal to 2 cm (T1a).2–5
Although lobectomy remains the standard of care for 
patients with stage IA NSCLC,6 limited resection is a surgical 
technique frequently used to treat patients who are not candi-
dates for a full lobectomy because of advanced age, severely 
compromised pulmonary function, or other comorbidities.7 
Moreover, results from observational studies,8 and a recent 
evaluation of the Surveillance, Epidemiology and End Results 
(SEER)-Medicare registry7 suggests that limited resection 
may be an adequate alternative for stage I NSCLC patients 
with T1a, particularly among the elderly.9–12 In cases where 
oncologic results are equivalent, potential benefits of limited 
resection include preserving vital lung tissue and providing 
the chance for further resection, if a second primary lung can-
cer develops. Thus, limited resection plays an important role 
in the treatment of patients with NSCLC who are diagnosed 
at an early stage.
The most common operative approaches for limited 
resection are wedge resection or segmentectomy. Wedge 
resection consists of the removal of a lung tumor with a sur-
rounding margin of normal lung parenchyma and is not an 
anatomical resection. Although technically more challenging, 
segmentectomy is considered by some to be the procedure of 
choice for limited surgery as it is an anatomical resection that 
usually includes a more extensive lymph node dissection.13 
However, there is very limited data comparing the outcomes 
of stage I patients treated with these procedures, which makes 
choices regarding the best surgical approach for patients 
undergoing limited resection more difficult.14
In this study, we used data from the SEER registry, a 
nationally representative, population-based source of cancer 
data, to assess whether survival of stage IA patients treated 
with segmentectomy is better than the patients undergoing 
wedge resection.
PATIENTS AND METHODS
Study patients were identified from the SEER data-
base, a national registry, sponsored by the National Cancer 
Copyright © 2012 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/12/0801-73
Survival After Segmentectomy and Wedge Resection in 
Stage I Non–Small-Cell Lung Cancer
Cardinale B. Smith, MD, MSCR,*† Scott J. Swanson, MD,‡ Grace Mhango, MPH,§  
and Juan P. Wisnivesky, MD, DrPH§ǁǁ
*Divisions of Hematology/Oncology, Tisch Cancer Institute, and †Hertzberg 
Palliative Care Institute of the Brookdale Department of Geriatrics, Mount 
Sinai School of Medicine, New York, New York; ‡Division of Thoracic 
Surgery, Brigham and Women’s Hospital, Boston, Massachussetts; and 
Divisions of §General Internal Medicine and ǁPulmonary, Critical Care and 
Sleep Medicine, Mount Sinai School of Medicine, New York, New York.
Disclosure: Dr. Wisnivesky is a member of the research board of Executive 
Health Exams International and has received lecture fees from Novartis 
Pharmaceutical and a research grant from GlaxoSmithKline. The other 
authors declare no conflict of interest.
Address for correspondence: Cardinale B. Smith, MD, MSCR, One Gustave 
L. Levy Place, Box #1079, New York, NY 10029. E-mail: cardinale.
smith@mssm.edu
ORIGINAL ARTICLE
74 Copyright © 2012 by the International Association for the Study of Lung Cancer
Smith et al. Journal of Thoracic Oncology  •  Volume 8, Number 1, January 2013
Institute, which collects data on all incident cancer cases in 
selected areas of the United States, covering nearly 26% of 
the U.S. population.15 The cohort was limited to cases with 
pathologically confirmed stage IA NSCLC (≤3 cm in size) 
diagnosed between 1998 and 2006, who underwent wedge 
resection or segmentectomy. Patients diagnosed before 1998 
were excluded as there were no details in SEER about the type 
of resection performed. We excluded patients who received 
preoperative radiation therapy (RT) as these patients may have 
had a clinically higher stage at the time of diagnosis. We also 
excluded individuals who had central lesions as they would 
not typically be amenable to wedge resection.
SEER provides baseline sociodemographic data, such 
as age, sex, race/ethnicity, and marital status. It also con-
tains detailed cancer information, including data about tumor 
location, size, and histology. Histologic subtypes were clas-
sified into categories of adenocarcinoma, bronchioalveolar 
cell carcinoma, squamous cell carcinoma, large cell carci-
noma, and other histologic types. Tumor histology is coded in 
SEER, using the International Classification of Diseases for 
Oncology, 3rd edition.16
Patients were classified as having undergone wedge 
resection (SEER surgical code 21) or segmentectomy (SEER 
surgical code 22) based on information included in the SEER-
site–specific surgery variable. The number of lymph nodes 
(LNs) sampled during surgery is also reported in the SEER 
registry. Postoperative use of external beam RT was ascer-
tained using specific codes provided in SEER. Postoperative 
RT is reported in SEER, if it is performed within 4 months of 
diagnosis as part of the primary treatment.
Survival was calculated as the period from diagnosis 
until death or last follow-up. Those surviving past December 
31, 2008 were classified as censored observations (alive at 
the end of follow-up). For the models estimating lung cancer-
specific survival, deaths attributed to causes other than lung 
cancer were censored at the date of death. The cause of death 
is coded in SEER based on the state death-certificate data. The 
study was reviewed by the Institutional Review Board and 
classified as exempt.
Statistical Analysis
We used the χ2 test to compare baseline characteristics 
of patients who underwent wedge resection or segmentectomy. 
Unadjusted survival of patients treated with segmentectomy 
and wedge resection were estimated using the Kaplan–Meier 
method and compared with the log-rank test. We used pro-
pensity score methods to control for potential differences in 
the baseline characteristics of patients treated with these two 
operative techniques. For the purpose of this study, the pro-
pensity score is a measure of the probability that a patient will 
undergo segmentectomy solely on the basis of his/her charac-
teristics before surgery. We calculated propensity scores using 
a logistic regression model that included age, sex, race/eth-
nicity, marital status, and tumor characteristics (location, size, 
and histology). Once the model was fitted, we used regression 
analysis to evaluate whether the baseline covariates were bal-
anced across the two study groups after adjusting for the esti-
mated propensity scores.
Cox regression analysis was used to compare over-
all and lung cancer-specific survival of patients treated with 
wedge resection or segmentectomy, controlling for propensity 
scores. First, we fitted a Cox model that included the propen-
sity score as a continuous covariate. Then, a Cox model was 
estimated within five strata defined by propensity score quin-
tiles. Finally, we matched patients treated with segmentectomy 
and wedge resection based on their propensity scores and then 
compared survival among those groups using a Cox model for 
correlated data.17 Prior studies using SEER data have shown 
that the number of LNs evaluated during surgery (a proxy 
of adequate LN staging) is a strong predictor of survival for 
stage I NSCLC.18 Thus, all Cox models were adjusted for the 
number of LNs evaluated, which was not included in the pro-
pensity score models because it was not a presurgical factor. 
We performed secondary analyses limited to patients with T1a 
tumors to assess whether wedge resection is equivalent to seg-
mentectomy for these smaller tumors. We also evaluated the 
effect of age (≤70 versus >70 years) on survival, given that 
prior data suggested that older patients may have good out-
comes after less-aggressive procedures.
RESULTS
A total of 3525 patients were included in the analysis 
and 704 (20%) of them underwent a segmentectomy. The base-
line characteristics of patients are reported in Table 1. There 
were no differences in age (p = 0.71), sex (p = 0.35), race/
ethnicity (p = 0.22), or histology (p = 0.63) between the two 
resection groups. Patients undergoing segmentectomy were 
more likely to be married (p = 0.04), had tumors located in the 
lower lobe of the lung (p = 0.004), had a larger tumor size (p 
<0.0001), had a higher number of LNs sampled (p < 0.0001), 
and were less likely to receive postoperative RT (p<0.0001). 
After adjustment for propensity scores, pretreatment charac-
teristics were balanced among patients who underwent wedge 
resection or segmentectomy.
Analyses using a Cox model, which included the pro-
pensity score and the number of LNs evaluated during sur-
gery as covariates showed that segmentectomy was associated 
with a significantly better overall (hazard ratio [HR]: 0.80, 
95% confidence interval [CI]: 0.69–0.93) and lung cancer-
specific survival (HR: 0.72, 95% CI: 0.59–0.88; Table 2). 
The survival advantage of segmentectomy (overall and lung-
cancer-specific) persisted when the analyses were repeated 
using stratification or matching of study patients by propen-
sity scores. Secondary analyses showed that overall (HR: 
0.81, 95% CI: 0.67–0.99) and lung cancer-specific survival 
(HR: 0.75, 95% CI: 0.58–0.98) was also better after segmen-
tectomy compared with wedge resection among patients with 
T1a tumors. When the analysis was restricted to patients aged 
70 years or younger, the overall (HR: 0.70, 95% CI: 0.54–
0.90) and lung-cancer-specific survival (HR: 0.73, 95% CI: 
0.54–0.99) advantage of segmentectomy persisted. Among 
patients aged more than 70 years, overall survival was not 
significantly better with segmentectomy (HR: 0.86, 95% CI: 
0.71–1.03); however, a lung cancer-specific survival advan-
tage of segmentectomy was still observed (HR: 0.69, 95% CI: 
0.53–0.90). Finally, when the analysis was limited to patients 
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who did not receive postoperative RT, overall (HR: 0.83, 95% 
CI: 0.71–0.98) and lung cancer-specific survival (HR: 0.76, 
95% CI: 0.61–0.94) was significantly better among patients 
who underwent segmentectomy.
DISCUSSION
Limited resection is frequently used to treat patients 
with stage IA NSCLC who are considered to be at high risk 
for complications or mortality with lobectomy. Although 
segmentectomy and wedge resection are the two operative 
approaches that can be used for the treatment of these patients, 
data to guide surgeons on the type of limited resection that 
yields the best outcomes are sparse. Using population-based 
data, we found that segmentectomy is associated with signifi-
cantly better survival in patients with stage IA NSCLC, which 
suggests that increased use of segmentectomy would decrease 
lung cancer deaths. These results should be validated in pro-
spective randomized trials.
Although wedge resection and segmentectomy have 
been combined in reports of outcomes after a limited resec-
tion, few studies have directly compared the survival out-
comes after these surgical techniques.14 One retrospective, 
single-institution study reported outcomes of 87 patients with 
stage IA NSCLC, who were unable to tolerate a lobectomy 
because of cardiopulmonary impairment. The study showed 
a significantly better lung cancer-specific survival (p = 0.016) 
and lower rates of local recurrence (p = 0.001) among patients 
TABLE 1.  Baseline Characteristics of Patients with Stage IA Non–Small-Cell Lung Cancer Treated with Limited Resection in 
Surveillance, Epidemiology and End Results Medicare, 1998–2006
Characteristic
Wedge Resection  
n=1568
Segmentectomy 
n=378
p
Without Adjustment With Adjustmenta
Age (years), mean ± SD 70 ± 9 70 ± 10 0.85 0.99
Sex n (%)
Male 699 (45) 162 (43) 0.55 0.99
Female 869 (55) 216 (57)
Race, n (%)
White 1345 (86) 315 (83) 0.35 0.71
Hispanic 46 (3) 19 (5)
African American 110 (7) 29 (8)
Other 67 (4) 15 (4)
Marital status, n (%)
Married 1518 (54) 409 (58) 0.04 0.98
Not married 1303 (46) 295 (42)
Histology, n (%)
Adenocarcinoma 808 (51) 190 (50) 0.94 0.80
Squamous cell carcinoma 401 (26) 104 (28)
Large cell carcinoma 69 (4) 17 (4)
BAC 187 (12) 45 (12)
Others 103 (7) 22 (60)
Tumor size (cm), mean ± SD 1.82 ± 0.06 1.95 ± 0.06 <0.0001 0.88
Location, n (%)
Upper 1042 (66) 225 (59) 0.03 0.94
Middle 59 (4) 12 (3)
Lower 453 (30) 139 (38)
Number of LNs examined, n (%)
≤1 1053 (67) 171 (45) <0.0001 —b
2–3 175 (11) 78 (20)
4–6 121 (8) 44 (12)
≥7 117 (8) 44 (12)
Unknown 102 (6) 41 (11)
Radiation therapy
No 1442 (92) 365 (97) <0.0001 __b
Yes 126 (8) 13 (3)
aAdjusted for propensity scores.
bThese variables were not included in the propensity score model as it is not a presurgical event.
SD, standard deviation; LNs, lymph nodes; BAC, bronchoalveolar carcinoma.
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who had a segmentectomy. Moreover, when the analysis was 
limited to patients with T1a tumors, the survival advantage 
after segmentectomy persisted. Conversely, Okada et al.12 per-
formed a nonrandomized study in which intentional sublobar 
resections were performed on 305 patients with stage IA hav-
ing T1a tumors, who could otherwise tolerate a lobectomy. 
In this study, wedge resection yielded a lung cancer-specific 
(p = 0.278) and overall survival (p = 0.106) equivalent to that 
of segmentectomies and lobectomies.12 These negative results 
may reflect the limited power of the study to identify differ-
ences in survival among groups. These studies, however, were 
conducted among a small and selected group of patients from 
single referral centers. Thus, our study provides important 
additional data about the survival outcomes after these pro-
cedures, as it used a large population-based sample of stage 
IA NSCLC patients from several geographical regions in the 
United States.
Although several factors have been associated with sur-
vival after resection of patients with stage I NSCLC, tumor 
size and the number of LNs evaluated during surgery seem to 
be among the most important.19,20 Tumor size is an important 
prognostic indicator in patients with stage I NSCLC, with bet-
ter prognosis in patients with T1a tumor.9,11,21–23 These patterns 
have been recognized in the new American Joint Committee 
on Cancer system that classifies tumors into T1a(≤2 cm), T1b 
(>2 to ≤3 cm), T2a (>3 to ≤5 cm), T2b (>5 to ≤7 cm), and T3 
(>7 cm).24 Thus, we performed secondary analyses in patients 
with T1a primary tumors to assess whether wedge resection 
may be equivalent to segmentectomy. We found a significant 
improvement after segmentectomy in overall and lung cancer-
specific survival among patients with T1a tumors, suggesting 
that segmentectomy may be a superior treatment, regardless 
of tumor size. The number of LNs evaluated during surgery 
also has important prognostic implications. Higher num-
bers of LNs sampled during surgery improves the accuracy 
of pathologic staging, avoiding misclassification of patients 
with LN involvement as having stage I disease.18 In the study 
cohort, segmentectomies were associated with a higher num-
ber of LNs sampled , a factor that could partially explain the 
association between segmental resection and improved sur-
vival. However, our adjusted analyses showed that segmen-
tectomy was associated with improved survival even after 
controlling for the number of LNs sampled during surgery. 
Our results also highlight the importance of adequate LN 
sampling when performing wedge resection, to avoid under-
staging, and to ensure appropriate use of adjuvant therapies 
among these patients.
Elderly patients with NSCLC are often not considered 
candidates for lobectomy, because of increased risk of peri-
operative mortality, a lower pulmonary reserve, and a lim-
ited life expectancy.25–27 For example, in an analysis by the 
SEER database of NSCLC patients offered curative intent 
surgeries, elderly patients were more likely to havea limited 
resection when compared with their younger counterparts.26 
Although there has been no direct comparison of segmentec-
tomy to wedge resection in the elderly, Jaklitsch et al.28 evalu-
ated elderly patients aged 75 years or more, who had either a 
wedge resection or an anatomical resection (defined as pneu-
monectomy, lobectomy, and segmentectomy). This study dem-
onstrated no difference in overall survival between wedge and 
anatomical resection.28 To address this issue, we performed 
secondary analyses, exploring whether segmentectomy was 
associated with improved survival among patients aged70 
years or younger and those more than 70 years of age. Among 
younger patients, segmentectomy was associated with better 
outcomes; however, for patients aged more than 70 years, only 
a lung cancer-specific survival advantage was observed with 
the use of segmentectomy. These findings may be explained by 
the fact that some older patients may have a limited life expec-
tancy, and thus, have a lower risk of lung cancer recurrence. 
However, as this is a subgroup analysis, we had limited power 
to detect differences in survival among older adults. Further 
studies are necessary to evaluate the equivalency of segmen-
tectomy and wedge resection among older NSCLC patients.
Some strengths and limitations of our study should be 
noted. This is a retrospective study, and as a result, allocation 
of patients to either wedge resection or segmentectomy was 
not random. Thus, it is possible that systematic differences in 
the baseline characteristics of patients, selected by their phy-
sicians to undergo these two procedures, may exist. These 
differences can confound survival comparisons among 
the two study groups. However, we used propensity score 
methods to balance the groups for all measured covariates. 
In the absence of randomized controlled trials comparing 
TABLE 2.  Results of Propensity Score Analysis Comparing 
Survival After Segmentectomy versus Wedge Resection
Model
Hazard Ratio (95% CI)a
Overall 
Survival
Lung Cancer-
Specific Survival
Primary analysis: entire cohort
 Adjusting for propensity scores 0.81 (0.69–0.96) 0.76 (0.61–0.94)
 St ratifying by propensity score 
quintiles
0.81 (0.69–0.95) 0.76 (0.61–0.94)
 Matched analysis 0.79 (0.69–0.90) 0.72 (0.60–0.86)
Secondary analyses
Limited to patients with tumors 
≤2 cm in size
 Adjusting for propensity scores 0.84 (0.68–0.99) 0.82 (0.62–1.00)
 St ratifying by propensity score 
quintiles
0.83 (0.67–1.00) 0.76 (0.58–0.98)
 Matched analysis 0.77 (0.66–0.91) 0.71 (0.58–0.88)
Limited to patients aged ≤70 years
 Adjusting for propensity scores 0.74 (0.56–0.96) 0.79 (0.57–1.00)
 St ratifying by propensity score 
quintiles
0.74 (0.57–0.98) 0.79 (0.57–1.00)
 Matched analysis 0.66 (0.52–0.83) 0.72 (0.54–0.94)
Limited to patients aged >70 years  
 Adjusting for propensity scores 0.85 (0.69–1.05) 0.73 (0.53–0.97)
 St ratifying by propensity Score 
quintiles
0.85 (0.69–1.04) 0.73 (0.55–0.98)
 Matched analysis 0.82 (0.69–0.97) 0.68 (0.54–0.86)
aHazard ratio for a patient undergoing segmentectomy versus wedge resection.
CI, confidence interval.
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these two treatments, propensity score methods is a useful 
method of analysis to compare these two treatment groups. 
Although SEER contains information of the important 
prognostic features among patients with stage IA NSCLC 
(including age, sex, tumor size, LN status, and number of 
LNs resected), there are no data on comorbidity, patient’s 
preoperative lung function, functional status, or recurrence 
rates. However, our analysis, using lung cancer-specific 
survival, which is closely related to recurrence rates and 
allows for controlling for other causes of death, also showed 
improved outcomes after segmentectomy. Similarly, we did 
not have information on resection margins. Thus, we could 
not evaluate whether the decreased survival among patients 
who underwent wedge resection may have been caused, in 
part, by a higher rate of positive margins. However, using 
lung cancer-specific survival, which is identified from death 
certificates, is a validated way of assessing lung cancer-spe-
cific death and controls for other causes of death.29–31 For the 
purposes of our analyses, we assumed that the segmentec-
tomies performed consisted of a true anatomical approach, 
with individual segmental bronchial and vascular isolation 
and division. Although there is no way to confirm this using 
the SEER database, the surgical procedure performed was 
coded as a segmentectomy, reflecting the interpretation of 
the surgeons performing the procedure. In addition, the 
validity of surgical codes in SEER has been reported, and 
stringent assurance policies are followed, to generate qual-
ity data. Similarly, the way in which the wedge or segmen-
tectomy was performed (open versus video-assisted thoracic 
surgery [VATS]) is not reported in SEER. Performing a seg-
mentectomy using VATS is technically more challenging, 
and often a VATS wedge may be performed on patients who 
are more sick. Patients who underwent wedge resection had 
a fewer number of LNs resected than those who underwent 
segmentectomy. However, the number of LNs resected was 
adjusted in the final Cox model. Thus, these results should 
more accurately reflect survival among these two treatment 
groups. In addition, patients who underwent wedge resection 
were more likely to receive postoperative RT. Some studies 
suggest that postoperative RT may be associated with worse 
outcomes among patients with stage I NSCLC, which may 
partially explain the survival advantage of segmentectomy 
in our study.32,33 However, rates of RT were low and rela-
tively similar among groups. Moreover, because this was an 
intention-to-treat analysis, we did not adjust for RT as this 
was a postoperative event. Finally, SEER contains popula-
tion-based data and thus, the generalizability of our findings 
should be strong. Moreover, the large number of patients in 
SEER allowed us to obtain relatively precise long-term sur-
vival estimates for patients undergoing wedge resection and 
segmentectomy, which would not have been possible from 
more detailed samples from single institutions.
In summary, these results suggest that segmentectomy 
compared with wedge resection may lead to improved survival 
among patients with stage IA NSCLC. As limited resection is 
increasingly used to treat patients who cannot tolerate a full 
lobectomy, and as its role is being evaluated as the primary 
treatment of T1a tumors, these results should be further evalu-
ated in prospective randomized trials.
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